The Scotts Miracle-Gro Company
SMG Details
The Scotts Miracle-Gro Company (NYSE: SMG) is among the world’s most prominent brands of branded consumer products for lawn and garden care. It has the industry’s most recognized brands, and its Scotts®, Miracle-Gro® and Ortho® brands are market-leading in their categories.
Result Performance for the First Quarter Ended 1 January 2022 – (Q1FY22)
- The sales stood at $566.0 million in Q1FY22, down 24%, primarily driven by Hawthorne segment that fell 38% to $190.6 million on the over-supply of cannabis rise in state-authorized markets that resulted in temporary fall in commercial cultivation activity.
- The GAAP and non-GAAP adjusted gross margin stood at 21.0% and 26.7%, respectively, primarily led by a fall in fixed cost leverage, higher material, and warehousing & distribution costs.
- The GAAP loss from continuing operations stood at $50.0 million, or $0.90 per share in Q1FY22, versus income of $25.2 million, or $0.43 per share in Q1FY21.
Source: Company Reports, Analysis by Kalkine Group
Key Updates
- On 30 March 2022, RIV Capital announced a definitive contract to acquire ownership and control of Etain LLC and Etain IP LLC for ~US$247 million through cash and newly issued Class A common shares of RIV Capital.
- On 8 March 2022, the company decreased its FY22 sales guidance for its Hawthorne segment, leading to lower adjusted earnings per share.
- On 16 February 2022, Scotts Company LLC and Major League Baseball plans to begin accepting submissions for the 2022 Scotts Field Refurbishment Grant Program.
Outlook
The company has guided achieving company-wide sales growth of 0-3% in FY22 with the U.S. Consumer segment sales is expected to remain between 2 to negative 2%. Moreover, the non-GAAP adjusted EPS is likely to stay in a range of $8.50-$8.90 and the gross margin is expected to decline by around 100 to 150 basis points. Besides, the company highlighted that it intends to repurchase up to another $300 million in shares during FY22 in addition to the $113 million of share repurchases undertaken in FY21.
The company expects Hawthorne sales to fall by 15-25%, including the benefit of acquisitions, primarily due to the oversupply of cannabis, leading to a fall in both indoor and outdoor cultivation. This slowdown in cultivation would impact the FY22 financials of the company.
Key Risks
The prevailing COVID-19 pandemic could adversely impact its business, results of operation, financial condition, and/or cash flows. Further, it is exposed to the risk of changes in regulations or regulatory enforcement priorities that could lead to an increase in its costs or restrict its ability to market all its products. It is also prone to climate change and unfavorable weather conditions that could adversely affect its financial results.
Valuation Methodology: EV/EBITDA Based Relative Valuation (Illustrative)
Technical Overview
Daily Price Chart
Source: REFINITIV, Note: Purple color line reflects Relative Strength Index (14-Period)
Stock Recommendation
The company has delivered a 6-month and one-year return of ~-17.34% and ~-52.04%, respectively. The stock is trading lower than the average price of the 52-week low-high range at $110.89–$254.14, respectively.
The stock has been valued using EV/EBITDA multiple based relative valuation (on an illustrative basis). The target price so arrived reflects a rise of low double-digit (in % terms). A slight premium has been applied to peer average EV/EBITDA multiple (NTM basis), considering a decent outlook for FY22 and its intention to take an inorganic route for growth.
Considering the factors above, we give a “Speculative Buy” recommendation on the stock at the current market price of US$118.18 per share, as on 09:16 am New York Time, USA (GMT-4) as of 06 April 2022.
Markets are trading in a highly volatile zone currently due to certain macro-economic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.
The Scotts Miracle-Gro Company (SMG) is a part of Kalkine’s Global Big Money Product
Note 1: The reference data in this report has been partly sourced from REFINITIV.
Note 2: Investment decisions should be made depending on the investors’ appetite on upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the analysis has been achieved and subject to the factors discussed above alongside support levels provided.
Technical Indicators Defined:-
Support: A level where-in the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.
Resistance: A level where-in the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.